161 results
8-K
EX-99.1
NGNE
Neurogene Inc
22 Apr 24
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
4:44pm
of Neurogene, including, but not limited to, statements regarding: the therapeutic potential and utility, efficacy and clinical benefits of NGN-401
8-K
EX-99.1
NGNE
Neurogene Inc
18 Mar 24
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
4:10pm
to, statements regarding: the therapeutic potential and utility, efficacy and clinical benefits of NGN-401; the safety
Exhibit 99.1
and tolerability profile
8-K
EX-99.2
NGNE
Neurogene Inc
4 Mar 24
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett
7:30am
the therapeutic potential and utility, efficacy and clinical benefits of NGN-401 and NGN-101; the safety and tolerability profile of NGN-401 and NGN
8-K
EX-99.1
q57drpdkv3uto5hy
4 Mar 24
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett
7:30am
S-8
EX-99.3
06mia 4dga306o2
20 Feb 24
Registration of securities for employees
4:16pm
S-8
EX-99.1
61yl5b9
20 Feb 24
Registration of securities for employees
4:16pm
S-8
EX-99.2
sz441qp
20 Feb 24
Registration of securities for employees
4:16pm
8-K
EX-10.28
d28 4ke5c
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.23
aiecsc7a
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.29
r1j8x
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.6
1anloc8piue2
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-99.3
3qo3rb3pw5suzyw259t
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.20
wxq c3nc22mmtb68
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.22
tuf1vvhwm rij46ql5
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-14.1
fcg63qls9frjei
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-99.4
xq7kj
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.24
4jgh8ccn 6boqbi1o4h
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.27
8yu0iqd 0o
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am